News
Lilly announces additional doses of neutralizing antibody therapy purchased by U.S. government to treat COVID-19
The U.S. government has agreed to purchase a minimum of 100,000 doses of bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1400 mg together, Eli...
News
Junshi Biosciences, AstraZeneca enter collaboration to commercialize toripalimab in China
Junshi Biosciences, a leading innovation-driven biopharmaceutical company, announced that the company has entered into an exclusive promotion agreement with AstraZeneca Pharmaceutical Co., Ltd, pursuant...
News
Novo Nordisk invests DKK 500 million in expanding tablet production facilities in Denmark
Novo Nordisk announced plans to invest DKK 500 million in expanding facilities at its production site in Måløv, Denmark.
The facility currently manufactures products for...
News
BMS Expands Cell Therapy Manufacturing Capabilities
Construction is underway for a new cell therapy manufacturing facility in Devens, MA, a part of Bristol Myers Squibb’s significant investment to support clinical...
Articles
The Impact of COVID-19 on Rare Disease Clinical Trials
Barriers and triumphs of an underserved patient group.
It is undeniable that clinical trials for rare diseases are more challenging to design and execute. Unlike...
News
Arcline Investment Management acquires ChargePoint Technology to fuel increased global presence
Sterile and contained pharmaceutical product transfer specialist, ChargePoint Technology (“ChargePoint” or the “Company”), has today announced that it has been acquired by Arcline Investment...
News
Phesi Collaborates with Alfasigma on Digital Transformation Project for Clinical Development and Commercialization
Phesi Inc., a leading provider of AI-based clinical development analytics products and solutions, is showcasing its data-driven clinical development approach at SCOPE Virtual Summit...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read